EcoDrugPlus

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSCCRG00000040006
Gene Symbol: LYN
1 Cross references
192 Possible Orthologues:

Mapk Activated Protein Kinase 2a

Ensembl ID : ENSCCRG00000062136
Gene Symbol: MAPKAPK2A
1 Cross references
142 Possible Orthologues:

Mapk Activated Protein Kinase 2a

Ensembl ID : ENSCCRG00000063236
Gene Symbol: MAPKAPK2A
1 Cross references
142 Possible Orthologues:

Mapk Activated Protein Kinase 2b

Ensembl ID : ENSCCRG00000038472
Gene Symbol: MAPKAPK2B
1 Cross references
169 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSCCRG00000035776
Gene Symbol: MAPKAPK5
1 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2a

Ensembl ID : ENSCCRG00000072905
Gene Symbol: MKNK2A
1 Cross references
152 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2a

Ensembl ID : ENSCCRG00000017949
Gene Symbol: MKNK2A
1 Cross references
153 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSCCRG00000066179
Gene Symbol: MKNK2B
1 Cross references
205 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSCCRG00000066026
Gene Symbol: MKNK2B
1 Cross references
205 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member A

Ensembl ID : ENSCCRG00000081622
Gene Symbol: MCL1A
1 Cross references
146 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member A

Ensembl ID : ENSCCRG00000072791
Gene Symbol: MCL1A
1 Cross references
146 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSCCRG00000058644
Gene Symbol: MCL1B
1 Cross references
227 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).